StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $3.65 | $3.61 | -1.10% | 0.0M |
| 05-18 | $3.53 | $3.47 | -1.70% | 0.0M |
| 05-19 | $3.46 | $3.35 | -3.18% | 0.0M |
| 05-20 | $3.34 | $3.32 | -0.60% | 0.0M |
| 05-21 | $3.28 | $3.23 | -1.52% | 0.0M |
No sell-side coverage available for SRTS yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $27.48M | $22.54M | $15.66M | $8.34M |
Operating Income | $-10.31M | $-7.16M | $-4.59M | $-2.65M |
Net Income | $-7.72M | $-4.55M | $-1.04M | $-2.57M |
EPS (Diluted) | $-0.47 | $-0.28 | $-0.22 | $-0.16 |
Total Assets | $53.04M | $58.30M | $58.85M | $60.21M |
Total Liabilities | $4.94M | $7.10M | $6.79M | $7.18M |
Cash & Equivalents | $22.08M | $24.45M | $22.16M | $19.07M |
Free Cash Flow OCF − CapEx | $332.00K | $2.70M | $406.00K | $-2.68M |
Shares Outstanding | 16.46M | 16.44M | 16.44M | 16.45M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.